1. Show article details.

    BRIEF-Sellas Life Sciences Announces Final Court Approval Of Settlement Of Derivative Litigation

    Reuters – 8:55 AM ET 11/23/2021

    Sellas Life Sciences Group Inc (SLS): * SELLAS LIFE SCIENCES ANNOUNCES FINAL COURT APPROVAL OF SETTLEMENT OF DERIVATIVE LITIGATION Source text for Eikon: Further company coverage:

  2. Show article details.

    SELLAS Life Sciences Announces Final Court Approval of Settlement of Derivative Litigation

    GlobeNewswire – 8:30 AM ET 11/23/2021

    SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that on November 19, 2021 the United States District Court for the District of New Jersey issued the final approval of the settlement of the claims relating to the Company’s predecessor, Galena Biopharma, Inc., and...

  3. Show article details.

    BRIEF-Sellas Life Sciences Reports Q3 Loss Per Share Of $0.45

    Reuters – 8:56 AM ET 11/12/2021

    Sellas Life Sciences Group Inc (SLS): * SELLAS LIFE SCIENCES REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE. * Q3 LOSS PER SHARE $0.45 Source text for Eikon: Further company coverage:

  4. Show article details.

    SELLAS Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update

    GlobeNewswire – 8:45 AM ET 11/12/2021

    SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today reported its financial results for the quarter ended September 30, 2021 and provided a business update.

  5. Show article details.

    SELLAS Life Sciences to Participate in Upcoming Conferences in October 2021

    GlobeNewswire – 9:14 AM ET 10/07/2021

    SELLAS Life Sciences Group (SLS), Inc. , a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that Angelos Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS, will participate in two upcoming conferences: For more information about the conferences, or to schedule a one-on-one meeting ...

  6. Show article details.

    BRIEF-Sellas Life Sciences Announces Settlement Of Derivative Litigation

    Reuters – 5:26 PM ET 09/23/2021

    Sellas Life Sciences Group Inc (SLS): * SELLAS LIFE SCIENCES ANNOUNCES SETTLEMENT OF DERIVATIVE LITIGATION. * Sellas Life Sciences Group Inc (SLS) - PRELIMINARY ORDER SET A FINAL SETTLEMENT APPROVAL HEARING FOR NOVEMBER 19, 2021 Source text for Eikon: Further company coverage:

  7. Show article details.

    SELLAS Life Sciences Announces Settlement of Derivative Litigation

    GlobeNewswire – 4:05 PM ET 09/23/2021

    SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that on September 10, 2021 the United States District Court for the District of New Jersey issued an order providing for preliminary approval of the proposed settlement of the claims relating to the Company’s prede...

  8. Show article details.

    SELLAS Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 28th

    GlobeNewswire – 8:30 AM ET 09/14/2021

    SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that Angelos Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS, will present at the 2021 Cantor Global Healthcare Conference to be held virtually on Tuesday, September 28, 2021, at 4:00 p.m. ET.

  9. Show article details.

    SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update

    GlobeNewswire – 4:22 PM ET 08/12/2021

    Reported Promising Updated Clinical Data in Ongoing Clinical Trials of Galinpepimut-S in Combination with PD-1 Inhibitors for Malignant Pleural Mesothelioma and WT1+ Advanced Ovarian Cancer Recently Published Outcomes Data for Acute Myeloid Leukemia Patients Highlights Continued Unmet Need and Expanded Market Opportunity for GPS Cash Position of $29.9 million as of June 30, 2021 To Host Virtual...

  10. Show article details.

    SELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on August 17, 2021

    GlobeNewswire – 8:30 AM ET 07/28/2021

    Management Team to be Joined by Leading Cancer Researcher, Dr. Yair Levy, Director of Hematologic Malignancies at the Baylor University Medical Center, and Member of the REGAL Steering Committee SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that it will host a...

  11. Show article details.

    SELLAS Reports Promising Updated Clinical Data and Initial Immune Response Profiles from Ongoing Phase 1/2 Study of Galinpepimut-S (GPS) Combined with Keytruda for Treating WT1+ Advanced Ovarian Cancer

    GlobeNewswire – 8:55 AM ET 06/30/2021

    Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up  Immune Data Shows GPS Induced WT1-Specific Immune Responses with a Substantial Increase in Antigen-Reactive T-Lymphocytes Averaging +242% for CD8+ and +80.5% for CD4+ T-Cells from Baseline to 18 Weeks Post Treatment NEW YORK, June 30, 2021 -- SELLAS Life Sciences Gro...

  12. Show article details.

    SELLAS Reports Encouraging Updated Clinical Data from Ongoing Mesothelioma Study of Galinpepimut-S (GPS) Combined with Opdivo

    GlobeNewswire – 8:30 AM ET 06/24/2021

    Updated Data Show Median Overall Survival of 35.4 Weeks in Patients Treated With Combination Therapy for at Least One Month – Median Overall Survival in Relapse/Refractory Patients with Standard of Care is Approximately 28 weeks New and Updated Clinical and Translational Data Expected by End of Q4 2021 NEW YORK, June 24, 2021 -- SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharma...

  13. Show article details.

    SELLAS Life Sciences Announces Inclusion in Russell Microcap® Index

    GlobeNewswire – 9:05 AM ET 06/22/2021

    SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that the Company will be included in the Russell Microcap® Index effective after the U.S. market opens on Monday, June 28, 2021, as based on the preliminary list of additions.

Page:

Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

  • Nov
    12

    SLS announced Q3 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.